CVX-210
CVX-210 is a vaccine administration code used in immunisation information systems to identify a specific COVID-19 vaccine based on a non-replicating viral vector (ChAdOx1) platform. It corresponds to the Oxford/AstraZeneca COVID-19 vaccine, also known globally under trade names such as Vaxzevria and Covishield. The vaccine is formulated as a 0.5 mL dose containing the recombinant spike protein antigen of SARS-CoV-2 encoded by a chimpanzee adenovirus vector (ChAdOx1).
This code helps healthcare systems accurately record and exchange vaccine information across electronic health record systems, immunisation registries, and global health databases.
Meaning and Context of CVX Codes
CVX codes (Codes for Vaccines Administered) are numeric identifiers established to standardise vaccine record-keeping within public health and clinical information systems. Each code represents a specific vaccine formulation, platform, or manufacturer, ensuring uniformity in immunisation data across regions.
CVX-210 is designated as a non-US vaccine in the official CVX classification, meaning it is not authorised for use within the United States but is recognised internationally for data reporting and interoperability. The code ensures accurate representation of vaccines that are widely used in other parts of the world, such as the AstraZeneca–Oxford vaccine distributed under various brand names.
Description of the CVX-210 Vaccine
- Vaccine Type: COVID-19 vaccine based on a non-replicating viral vector (ChAdOx1).
- Active Component: Recombinant SARS-CoV-2 spike (S) glycoprotein gene encoded by a replication-deficient chimpanzee adenovirus vector.
- Formulation: 0.5 mL per dose, intramuscular injection.
- Common Trade Names: Vaxzevria, Covishield.
- Manufacturer Examples: AstraZeneca (UK–Sweden) and Serum Institute of India (under licence).
- Immunological Action: The vaccine stimulates the immune system to recognise and neutralise the SARS-CoV-2 virus by producing specific antibodies and activating T-cell responses.
Purpose and Usage
The CVX-210 code is used by national and international health systems for:
- Electronic Documentation: Accurate recording of COVID-19 vaccination events in immunisation databases.
- Interoperability: Facilitating exchange of vaccination records across countries and healthcare platforms.
- Data Analysis: Supporting public health monitoring, reporting, and vaccine coverage studies.
- Travel and Cross-border Verification: Recognising internationally administered vaccines in global health and travel documentation systems.
Global and Regional Relevance
CVX-210 represents one of the most widely used COVID-19 vaccines globally, particularly in India, the United Kingdom, Africa, and parts of Asia and Europe. In India, the Serum Institute of India’s Covishield vaccine—based on the same ChAdOx1 adenoviral vector—has been a major component of the national COVID-19 immunisation drive.
Although the AstraZeneca vaccine is not licensed in the United States, it has been authorised by the World Health Organization (WHO) for emergency use, ensuring its global recognition. The inclusion of CVX-210 in the vaccine coding system allows for harmonised recording and reporting of vaccination data worldwide.
Importance of CVX-210 in Health Information Systems
- Uniform Identification: Prevents ambiguity in vaccine data by assigning a distinct numerical code.
- Data Accuracy: Enables consistent documentation across different healthcare software and jurisdictions.
- Inter-National Recognition: Ensures that vaccines administered outside the US are identifiable in global health databases.
- Public Health Monitoring: Assists in tracking vaccine coverage, effectiveness, and safety across populations.
- Regulatory Compliance: Aligns with international health data standards for pandemic management and immunisation verification.
| Related | |
|---|---|
